We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals

By LabMedica International staff writers
Posted on 19 Oct 2023
Print article
Image: The bleeding risk diagnostic test determines blood clotting status and whether a patient is on blood thinners (Photo courtesy of FloBio)
Image: The bleeding risk diagnostic test determines blood clotting status and whether a patient is on blood thinners (Photo courtesy of FloBio)

Millions of people rely on Direct Oral Anticoagulants (DOACs) to manage conditions like atrial fibrillation and deep vein thrombosis. These medications are efficient but pose an increased risk of bleeding, making emergency medical treatment challenging. Current bedside diagnostics don't effectively assess the status of DOACs in a patient, complicating the management of bleeding during traumatic incidents, surgeries, strokes, and other health emergencies. Serious bleeding episodes associated with these anticoagulants can result in up to 20% mortality within a month, extend hospital stays, and increase the likelihood of readmission. Now, a rapid bleeding risk diagnostic test can evaluate blood clotting status and identify if a patient is taking DOACs. This knowledge allows emergency and critical care providers to make informed decisions on drug reversal, which can minimize severe bleeding, a significant cause of avoidable complications and fatalities in hospitals.

FloBio (Philadelphia, PA, USA) is developing the first accurate, point-of-care test to detect DOACs that will aid emergency medical staff in deciding whether to administer medications that counteract DOACs' effects. Designed for in-vitro diagnostic purposes, this automated test offers a complete picture of a patient's blood clotting status after factoring in the anticoagulant effects of these blood thinners. The innovative device platform integrates hemodynamic flow with discrete clot activation to mimic physiological blood clotting. This allows for a quick and thorough evaluation of DOAC levels right at the patient's bedside. The U.S. Food and Drug Administration has granted Breakthrough Device Designation for FloBio’s rapid bleeding risk diagnostic test.

"Every year hundreds of thousands of Americans taking DOACs experience emergencies. It is critical that physicians have tools to rapidly detect DOACs so they definitively know whether to proceed with drug reversal to safely manage patients," said Jerri Ann Thatcher, Founding CEO. “We are encouraged that the FDA has recognized that our device has the potential to provide more effective diagnosis and treatment of life-threatening diseases and conditions. Our team looks forward to working with the FDA to accelerate the development, assessment, and commercialization of our technology, which so clearly fills a void in the market.”

Related Links:
FloBio 

Platinum Supplier
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Gold Supplier
Rapid Flu Test
Influenza A&B Rapid Test Kit
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Supplier
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE

Print article

Channels

Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more

Molecular Diagnostics

view channel
Image: The PrismRA blood test helps target best treatments for patients with rheumatoid arthritis (Photo courtesy of Scipher Medicine)

Groundbreaking Rheumatoid Arthritis Blood Test Predicts Treatment Response

Rheumatoid arthritis (RA), an autoimmune disease affecting joints and other systems in the body, impacts millions globally. Typically, the initial biologic treatment involves anti-inflammatory drugs from... Read more

Immunology

view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more

Microbiology

view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more

Pathology

view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more

Industry

view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.